Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study

por Braun, Jürgen, Baraliakos, Xenofon, Deodhar, Atul, Poddubnyy, Denis, Emery, Paul, Delicha, Eumorphia M, Talloczy, Zsolt, Porter, Brian
Publicado 2019

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

por Kivitz, Alan J., Wagner, Ulf, Dokoupilova, Eva, Supronik, Jerzy, Martin, Ruvie, Talloczy, Zsolt, Richards, Hanno B., Porter, Brian
Publicado 2018

Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1

por Tseng, Jui-Cheng, Wei, James Cheng-Chung, Deodhar, Atul, Martin, Ruvie, Porter, Brian, McCreddin, Suzanne, Talloczy, Zsolt
Publicado 2020

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study

por Baraliakos, Xenofon, Braun, Juergen, Deodhar, Atul, Poddubnyy, Denis, Kivitz, Alan, Tahir, Hasan, Van den Bosch, Filip, Delicha, Evie-Maria, Talloczy, Zsolt, Fierlinger, Anke
Publicado 2019

Methamphetamine Inhibits Antigen Processing, Presentation, and Phagocytosis

por Tallóczy, Zsolt, Martinez, Jose, Joset, Danielle, Ray, Yonaton, Gácser, Attila, Toussi, Sima, Mizushima, Noboru, Nosanchuk, Josh, Goldstein, Harris, Loike, John, Sulzer, David, Santambrogio, Laura
Publicado 2008

Correction: Methamphetamine Inhibits Antigen Processing, Presentation, and Phagocytosis

por Tallóczy, Zsolt, Martinez, Jose, Joset, Danielle, Ray, Yonaton, Gácser, Attila, Toussi, Sima, Mizushima, Noboru, Nosanchuk, Joshua D., Goldstein, Harris, Loike, John, Sulzer, David, Santambrogio, Laura
Publicado 2008